off-the-wire

White House's Navarro says pharma tariffs likely under Section 232 probe

Kitco Media
By Reuters
Published:
Updated:
Reuters
White House's Navarro says pharma tariffs likely under Section 232 probe teaser image

WASHINGTON, Aug 14 (Reuters) - White House trade adviser Peter Navarro said on Thursday that the Trump administration is likely to levy tariffs on pharmaceutical imports under a "Section 232" trade investigation because it's "very clear that we have a national security crisis" due to U.S. reliance on foreign producers in the sector.

In an televised interview with CNBC, Navarro did not provide any details on the timing of the Section 232 probe.

He said that President Donald Trump's executive order to shore up supply chains will provide price floors for domestic producers of drug ingredients through long-term strategic contracts that will ensure sufficient demand. At the same time, tariffs will deter dumping of pharma precursors from India and China, he added.

Reporting by David Lawder; Editing by Mark Porter

Disclaimer: The views expressed in this article are those of the author and may not reflect those of Kitco Metals Inc. The author has made every effort to ensure accuracy of information provided; however, neither Kitco Metals Inc. nor the author can guarantee such accuracy. This article is strictly for informational purposes only. It is not a solicitation to make any exchange in commodities, securities or other financial instruments. Kitco Metals Inc. and the author of this article do not accept culpability for losses and/ or damages arising from the use of this publication.